Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,203,934
  • Shares Outstanding, K 156,039
  • Annual Sales, $ 1,094 M
  • Annual Income, $ -139,310 K
  • 36-Month Beta 1.79
  • Price/Sales 4.86
  • Price/Cash Flow 55.10
  • Price/Book 4.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.38
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.46
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.65 +6.28%
on 02/08/19
34.69 -6.11%
on 01/28/19
-1.57 (-4.60%)
since 01/18/19
3-Month
27.54 +18.26%
on 12/26/18
37.64 -13.47%
on 11/29/18
-1.78 (-5.18%)
since 11/21/18
52-Week
27.54 +18.26%
on 12/26/18
62.42 -47.82%
on 03/15/18
-30.62 (-48.46%)
since 02/21/18

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS

Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. ("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers and directors. The class action, filed...

ALKS : 32.57 (-2.34%)
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, ("Alkermes"...

ALKS : 32.57 (-2.34%)
CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

DBVT : 7.97 (-3.98%)
ALKS : 32.57 (-2.34%)
IMMU : 14.31 (-0.35%)
DXC : 66.11 (-0.50%)
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

VRTX : 183.06 (-2.54%)
CLVS : 24.18 (-0.25%)
GILD : 65.55 (-2.13%)
ICPT : 91.83 (-7.27%)
ALKS : 32.57 (-2.34%)
ALKS UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important Deadline in Securities Class Action - ALKS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alkermes Public Limited Company from February 17, 2017 through November 1, 2018, inclusive (the "Class Period")...

ALKS : 32.57 (-2.34%)
Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 27, 2019...

ALKS : 32.57 (-2.34%)
CLASS ACTION UPDATE for YOGA, ARLO, ALKS and GSM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

GSM : 2.18 (-4.39%)
YOGA : 0.57 (unch)
ARLO : 4.06 (+2.78%)
ALKS : 32.57 (-2.34%)
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, ALKS, MU and TAP

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies...

AXGN : 18.01 (+1.92%)
TAP : 62.08 (+1.12%)
MU : 41.53 (-1.61%)
ALKS : 32.57 (-2.34%)
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

NTEC : 9.12 (+2.01%)
VRTX : 183.06 (-2.54%)
CLVS : 24.18 (-0.25%)
GILD : 65.55 (-2.13%)
ICPT : 91.83 (-7.27%)
ALKS : 32.57 (-2.34%)
CLASS ACTION UPDATE for ARLO, PRGO, ALKS and ASTE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

ARLO : 4.06 (+2.78%)
ALKS : 32.57 (-2.34%)
ASTE : 39.45 (-0.70%)
PRGO : 48.32 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 33.74
1st Resistance Point 33.16
Last Price 32.57
1st Support Level 32.16
2nd Support Level 31.74

See More

52-Week High 62.42
Fibonacci 61.8% 49.10
Fibonacci 50% 44.98
Fibonacci 38.2% 40.86
Last Price 32.57
52-Week Low 27.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar